Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Youngstown, Ohio 44512


Purpose:

The objective of this study is to prospectively monitor the incidence of adverse drug reactions, specifically NSF during routine use of gadoversetamide in a large number of patients with moderate renal insufficiency (eGFR 30-59) and severe renal insufficiency or end-stage renal disease requiring dialysis (eGFR <30).


Criteria:

Inclusion Criteria: - Referred for contrast-enhanced MRI using gadoversetamide; - Have a documented estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2 within the past 6 months or ESRD requiring dialysis; and - Willing and able to provide written consent (themselves or by a legally authorized representative) and agree to abide by study requirements, including being seen by a dermatologist and undergoing a skin biopsy if NSF is suspected. Exclusion Criteria: - Have experienced a previous hypersensitivity reaction to a GBCA; - Have pre-existing NSF or NSF-like symptoms; or - Have been exposed to a GBCA within 12 months prior to the index procedure; or - Has a medical condition or other personal situation that would prevent providing follow-up information, completing clinic visits or otherwise supplying meaningful data to meet study objectives.


Study is Available At:


Original ID:

1177-07-868


NCT ID:

NCT00811863


Secondary ID:


Study Acronym:

SHERLOC


Brief Title:

Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection


Official Title:

A Prospective Study for the Detection of Nephrogenic Systemic Fibrosis in Patients With Renal Impairment Undergoing Gadoversetamide-enhanced Magnetic Resonance Imaging


Overall Status:

Withdrawn


Study Phase:

N/A


Genders:

N/A


Minimum Age:

N/A


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Guerbet


Oversight Authority:

United States: Food and Drug Administration


Reasons Why Stopped:

Study drug currently unavailable


Study Type:

Observational


Study Design:


Number of Arms:

0


Number of Groups:

2


Total Enrollment:

0


Enrollment Type:

Actual


Overall Contact Information

Official Name:Herbert R. Neuman, MD
Study Director
Mallinckrodt

Study Dates

Start Date:February 2009
Completion Date:May 17, 2012
Completion Type:Actual
Primary Completion Date:May 17, 2012
Primary Completion Type:Actual
Verification Date:August 2017
Last Changed Date:August 1, 2017
First Received Date:December 18, 2008

Study Outcomes

Outcome Type:Primary Outcome
Measure:The primary outcome measure will be the diagnosis of NSF based on clinical assessments and patient telephone calls through 24 months of follow-up.
Time Frame:1, 3, 6, 12, 18 and 24 months
Safety Issues:False

Study Interventions

There are no available Study Interventions

Study Arms

Study Arm Type:Other
Arm Name:1
Description:Subjects with moderate renal insufficiency defined as an eGFR 30-60 mL/min/1.73 m2
Study Arm Type:Other
Arm Name:2
Description:Subjects with severe renal insufficiency defined as an eGFR <30 mL/min/1.73 m2 and ESRD defined as requiring dialysis

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Guerbet

Samples and Retentions

Sample Retention:Samples Without DNA
Description: Serum; Plasma; Fixed tissue samples
Study Population: Subjects with moderate to severe renal insufficiency that have been identified as requiring (for any indication) a contrast-enhanced MRI using gadoversetamide.
Sample Method:Non-Probability Sample

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.